 | • レポートコード：MRC2205A104 • 出版社/出版日：Transparency Market Research / 2022年4月30日 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、世界の遺伝子治療市場について調査し、序論、仮定・調査手法、市場概要、キーインサイト、製品別（イエスカルタ、キムリア、ラクスターナ、ストリムベリス、ジェンディシン）分析、用途別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。 ・序論 ・仮定・調査手法 ・市場概要 ・キーインサイト ・世界の遺伝子治療市場規模：製品別（イエスカルタ、キムリア、ラクスターナ、ストリムベリス、ジェンディシン） ・世界の遺伝子治療市場規模：用途別 ・世界の遺伝子治療市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Gene Therapy Market – Scope of Report
TMR’s report on the global gene therapy market studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global gene therapy market for the period 2017–2028, considering 2020 as the base year and 2028 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global gene therapy market during the forecast period.
The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global gene therapy market.
Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global gene therapy market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global gene therapy market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global gene therapy market.
The report delves into the competitive landscape of the global gene therapy market. Key players operating in the global gene therapy market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global gene therapy market that have been profiled in this report.
Research Methodology
A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global gene therapy market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary methods referred to by analysts during the production of the global gene therapy market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the gene therapy market as primary methods.
These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the gene therapy market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global gene therapy market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global gene therapy market more reliably and accurately.
レポート目次 1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gene Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gene Therapy Market Analysis and Forecast, 2018–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Regulatory Scenario by Region/globally
5.3. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Gene Therapy Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2018–2030
6.3.1. Yescarta
6.3.2. Kymriah
6.3.3. Luxturna
6.3.4. Strimvelis
6.3.5. Gendicine
6.3.6. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Gene Therapy Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2018–2030
7.3.1. Ophthalmology
7.3.2. Oncology
7.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)
7.4. Market Attractiveness Analysis, by Application
8. Global Gene Therapy Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Global Gene Therapy Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product, 2018–2030
9.2.1. Yescarta
9.2.2. Kymriah
9.2.3. Luxturna
9.2.4. Strimvelis
9.2.5. Gendicine
9.2.6. Others
9.3. Market Value Forecast, by Application, 2018–2030
9.3.1. Ophthalmology
9.3.2. Oncology
9.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)
9.4. Market Value Forecast, by Country, 2018–2030
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Application
9.5.3. By Country
10. Europe Global Gene Therapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2018–2030
10.2.1. Yescarta
10.2.2. Kymriah
10.2.3. Luxturna
10.2.4. Strimvelis
10.2.5. Gendicine
10.2.6. Others
10.3. Market Value Forecast, by Application, 2018–2030
10.3.1. Ophthalmology
10.3.2. Oncology
10.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)
10.4. Market Value Forecast, by Country, 2018–2030
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Application
10.5.3. By Country
11. Asia Pacific Global Gene Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2018–2030
11.2.1. Yescarta
11.2.2. Kymriah
11.2.3. Luxturna
11.2.4. Strimvelis
11.2.5. Gendicine
11.2.6. Others
11.3. Market Value Forecast, by Application, 2018–2030
11.3.1. Ophthalmology
11.3.2. Oncology
11.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)
11.4. Market Value Forecast, by Country, 2018–2030
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Application
11.5.3. By Country
12. Latin America Global Gene Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2018–2030
12.2.1. Yescarta
12.2.2. Kymriah
12.2.3. Luxturna
12.2.4. Strimvelis
12.2.5. Gendicine
12.2.6. Others
12.3. Market Value Forecast, by Application, 2018–2030
12.3.1. Ophthalmology
12.3.2. Oncology
12.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)
12.4. Market Value Forecast, by Country, 2018–2030
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Application
12.5.3. By Country
13. Middle East & Africa Global Gene Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2018–2030
13.2.1. Yescarta
13.2.2. Kymriah
13.2.3. Luxturna
13.2.4. Strimvelis
13.2.5. Gendicine
13.2.6. Others
13.3. Market Value Forecast, by Application, 2018–2030
13.3.1. Ophthalmology
13.3.2. Oncology
13.3.3. Adenosine Deaminase‐Deficient Severe Combined Immunodeficiency (ADA-SCID)
13.4. Market Value Forecast, by Country, 2018–2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Application
13.5.3. By Country
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Company Profiles
14.2.1. Novartis AG
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.1.2. Financial Overview
14.2.1.3. Product Portfolio
14.2.1.4. SWOT Analysis
14.2.1.5. Strategic Overview
14.2.2. Orchard Therapeutics Limited
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.2.2. Financial Overview
14.2.2.3. Product Portfolio
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Celgene Corporation
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.3.2. Financial Overview
14.2.3.3. Product Portfolio
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Spark Therapeutics, Inc.
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.4.2. Financial Overview
14.2.4.3. Product Portfolio
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Gilead Sciences, Inc.
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.5.2. Financial Overview
14.2.5.3. Product Portfolio
14.2.5.4. SWOT Analysis
14.2.5.5. Strategic Overview
14.2.6. Sibiono GeneTech Co. Ltd.
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.6.2. Financial Overview
14.2.6.3. Product Portfolio
14.2.6.4. SWOT Analysis
14.2.6.5. Strategic Overview
14.2.7. Other prominent players
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.7.2. Financial Overview
14.2.7.3. Product Portfolio
14.2.7.4. SWOT Analysis
14.2.7.5. Strategic Overview